Phase I1 study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: An EORTC gynecological cancer cooperative group study

J. B. Vermorken, F. Landoni, S. Pecorelli, M. J. Piccart, M. Van Der Burg, W. W. Ten Bokkel Huinink, M. George, S. Greggi, N. Rotmensz

Research output: Contribution to journalArticle

Abstract

Vermorken JB, Landoni F, Pecorelli S, Piccart MJ, van der Burg MEL, ten Bokkel Huinink WW, George M, Greggi S, Rotmensz N. Phase I1 study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Int Gynecol Cancer 1991; 1: 248-252. Twenty-nine patients with disseminated squamous cell carcinoma of the uterine cervix were treated with a 3 mg/m2 weekly i.v. bolus schedule of vindesine for 6 weeks (thereafter every 2 weeks). Twenty-seven patients were evaluable for response, 19 of whom had received prior chemotherapy (14 also vincristine). Five of the 27 patients (19%) showed a partial response, all being part of the 22 patients with only distant metastases. No objective response were observed among five patients who also had loco-regional recurrent disease. The median duration of response was 21 (11-58) weeks. Dose-limiting toxic effects were leukopenia and peripheral neuropathy. Vindesine warrants further study in combination chemotherapy protocols for cervical cancer.

Original languageEnglish
Pages (from-to)248-252
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume1
Issue number6
Publication statusPublished - 1991

    Fingerprint

Keywords

  • Carcinoma of the cervix
  • Phase 11
  • Squamous cell
  • Vindesine

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Vermorken, J. B., Landoni, F., Pecorelli, S., Piccart, M. J., Van Der Burg, M., Ten Bokkel Huinink, W. W., George, M., Greggi, S., & Rotmensz, N. (1991). Phase I1 study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: An EORTC gynecological cancer cooperative group study. International Journal of Gynecological Cancer, 1(6), 248-252.